Oct 25, 2021

Avestria Ventures Invests in Wainamic's partner AmplifiDx

Wainamics congratulates AmplifiDx for securing funding from Avestria Ventures to develop a new point-of-care platform, the DX1000.  Wainamics is developing the cartridges for COVID-19 and other infectious diseases.

Under the Microscope: AmplifiDx


Avestria Ventures"invested in AmplifiDx because we believe the company’s DX 1000 system and testing capabilities offer a solution to a major testing dilemma...By offering PCR-level accuracy at a decreased cost, AmplifiDx can deliver both an accessible testing option and rapid results to individuals who are seeking resources."

Aug 5, 2021

Wainamics is working with scientists from UC Berkeley to develop a COVID-19 diagnostic test that is faster and easier than the current gold standard based on qRT-PCR. The new test is a CRISPR-based diagnostic assay that does not require amplification. Wainamics is integrating the new assay called Fast Integrated Nuclease Detection in Tandem (FIND-IT) onto a microfluidic cartridge.  More information about this research and development project can be found in this Berkeley News article.

Using two CRISPR enzymes, a COVID diagnostic in only 20 minutes

Feb 15, 2021

Wainamics has partnered with AmplifiDx to Develop the Next Generation Molecular Point-of-Care Platform

AmplifiDx,Inc. is developing the next generation molecular point-of-care platform with a very simple workflow: swab in-answer out.  Wainamics is responsible for developing the low cost disposable cartridges that contain all the required reagents for the platform.  Our rapid COVID viral testing system has completed RADx Phase 1 and is currently part of the RADx Next program. 

Nov 16, 2020

Wainamics in the Semi-Finals Round for the XPRIZE Rapid COVID Testing

Wainamics, together with our partners, is developing a Low Cost Swab to Answer, Rapid COVID Test and was selected as an XPRIZE Rapid Covid Testing semi-finalist.  The simple to use system consists of our low cost disposable cartridge that contains all required reagents, providing swab to answer results.


XPRIZE, a 501(c)(3) nonprofit, is the global leader in designing and implementing innovativecompetition models to solve the world’s grandest challenges. Active competitions include the$20 Million NRG COSIA Carbon XPRIZE, the $10 Million Rainforest XPRIZE, the $10 MillionANA Avatar XPRIZE, the $5 Million IBM Watson AI XPRIZE, $5 Million XPRIZE Rapid Reskilling,XPRIZE NextGen Mask Challenge and $5 Million XPRIZE Rapid COVID Testing. For moreinformation, visit

Nov 9, 2020

Wainamics would like to congratulate Jennifer Doudna and Emmanuelle Charpentier for winning the 2020 Nobel Prize in chemistry.  They developed CRISPR-Cas9, a revolutionary gene-editing tool that can change the DNA of plants and animals with extraordinary precision.  Wainamics is excited to be working on a project with Jennifer and the Innovative Genomics Institute to develop microfluidic cartridges that implement the CRISPR assay.


UC Berkeley’s Jennifer Doudna wins 2020 Nobel Prize in Chemistry 

Oct 30, 2020

Wainamics Working on NIH RADx Project to Develop a Rapid COVID Test

Wainamics has teamed up with strategic partners to develop a low cost COVID-19 rapid test that is easy to use and requires no special handling. This project is one of forty-six companies selected for Phase 1 of the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) Tech program. The RADx Tech program is accelerating the development, commercialization, and implementation of technologies for COVID-19 testing.  The simple system delivers results in less than 45 minutes and features a disposable cartridge for use in a compact, low-cost instrument. The Wainamics cartridge contains all required reagents that provides swab to answer results. 

CEO Ming Tan emphasized the importance of accessible and reliable tests to a safe return to everyday activities.  She commented, “Together with our capabilities in cartridge development and assay integration and the expertise of our partners, our team is capable of rapidly developing a robust, scalable, low-cost point-of-care system.”

This project is supported by the NIH Rapid Acceleration of Diagnostics (RADx   ) program and has been funded in whole or in part with federal funds from National Heart, Lung and Blood Institute, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Department of Health and Human Services, under Grant No. 3U54HL143541-02Sl.


Apr 28, 2020

Ming Tan, Ph.D. and Wainamics were recently featured on the Mammoth Interviews series. 

Mammoth Blog.png

Aug 5, 2019

The device Wainamics developed for Purdue University spin-off OmniVis was featured on NPR news.  

This Handy New Device Might Help KO Cholera


Jun 7-10, 2021

Wainamics hosted a virtual booth at CYTO 2021. 

Mar 1-4, 2020

Wainamics exhibited at the 27th International Molecular Medicine Tri-Conference in San Francisco, CA.  Ming Tan, Ph.D. presented "Point-of-Care, Quantitative Procalcitonin Test Using Electrochemistry Sensors" as part of the Enabling Point-of-Care Technologies track.

Oct 7-9, 2019

Wainamics presented a poster on "Critical Components for Lab-on-a-Chip Product Development" at Lab-on-a-Chip & Microfluidics World Congress in San Diego, CA.

Aug 6-8, 2019

Wainamics exhibited at the 2019 AACC Annual Scientific Meeting and Clinical Lab Expo in Anaheim, CA.

Mar 11-13, 2019

Wainamics exhibited at the 26th International Molecular Medicine Tri-Conference in San Francisco, CA.